Pituitary apoplexy by Wichlińska-Lubińska, Małgorzata & Kozera, Grzegorz
413www.journals.viamedica.pl/neurologia_neurochirurgia_polska
Neurologia i Neurochirurgia Polska
Polish Journal of Neurology and Neurosurgery
2019, Volume 53, no. 6, pages: 413–420
DOI: 10.5603/PJNNS.a2019.0054 
Copyright © 2019 Polish Neurological Society 
ISSN 0028–3843
REVIEW ARTICLE
Address for correspondence: Małgorzata Wichlińska-Lubińska, Department of Neurology, University Hospital No 1 M. Skłodowskiej-Curie, 9 Str.,  
85–094 Bydgoszcz, Poland, phone: +48 501 122 277, fax.: +48 52 585 40 32, e-mail: wichlinska@o2.pl
Pituitary apoplexy
Małgorzata Wichlińska-Lubińska, Grzegorz Kozera
Department of Neurology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Poland
ABSTRACT
Pituitary apoplexy (PA) is a clinical syndrome caused by acute haemorrhage and/or infarction of the pituitary gland, generally 
within a frequently undiagnosed pituitary adenoma. The sudden increase in pituitary gland volume is responsible for typical 
symptoms: severe headache, nausea, vomiting, visual impairment, cranial nerve palsies, deteriorating level of consciousness, 
and hypopituitarism. Radiological evidence, especially magnetic resonance imaging (MRI) which is the most sensitive diagnostic 
modality, establishes the diagnosis. Multiple risk factors have been reported, although the majority of cases have no identifiable 
precipitants. The management strategy depends on the clinical manifestation, as well as the presence of co-morbidities, and 
remains controversial. Post apoplexy, there needs to be careful monitoring for recurrence of tumour growth and endocrinolo-
gical function of the pituitary. This disease is rare but potentially life-threatening without rapid treatment. Because there are no 
randomised studies, it is suggested that further trials are needed to optimise proper management.
Key words: pituitary apoplexy, pituitary adenoma, hypopituitarism, management, outcome 
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Introduction
Pituitary apoplexy (PA) is defined as an acute clinical syn-
drome caused by sudden haemorrhage and/or infarction of the 
pituitary gland, generally within a pituitary adenoma [1]. The 
first description of a clinical presentation is attributed to Bailey 
in 1898 [2]. The term ‘pituitary apoplexy’ was coined by Brog-
ham et al. in 1950 [3]. The term ‘subclinical pituitary apoplexy’ 
was later applied for an asymptomatic pituitary haemorrhage 
identified during radiological investigation or during a patholo-
gical examination. However, PA is a clinical diagnosis, and the 
term should be reserved only for the classical presentation [4]. 
The outcome of apoplexy is difficult to predict: the patient’s 
clinical condition can deteriorate dramatically or improve 
spontaneously, with or without sequelae. Apoplexy sometimes 
destroys the pituitary adenoma, but regrowth from a tumour 
remnant may occur in other cases [1]. Although rare, the 
condition must be recognised and properly treated, as it may 
be life-threatening [3]. 
There are no randomised controlled trials on the optimal 
management of this condition. Management has mostly de-
pended on conclusions drawn from several case series and 
expert opinion. There are several controversies in dealing 
with this rare neuroendocrine emergency, including whether 
a conservative procedure or surgery should be the first-line 
strategy, and the optimal timing of any such surgery [5].
Epidemiology
Pituitary apoplexy is rare, with an estimated prevalence 
of 6.2 cases per 100,000 inhabitants [6] and an incidence of 
0.17 episodes per 100,000 person-years [7]. PA can occur at 
all ages, but is most frequent in the fifth or sixth decades, with 
a preponderance in males [1, 3], who are affected in 60–67% 
of cases [4]. Its exact prevalence is difficult to estimate because 
many cases remain undiagnosed, but it seems to occur in 0.6-
10.5% of pituitary adenomas [8]. 
Pituitary apoplexy may represent the first presentation 
of a pre-existing, unrecognised adenoma in 60–80% of cases 
[3, 9]. Macroadenomas are most susceptible to apoplexy, but 
apoplexy in microadenomas has been reported [10]. The 
most frequent type of pre-existing adenoma appears to be the 
non-functioning pituitary adenoma (NFPA), accounting for 
45–82% of PA cases [4]. Prolactinomas and growth hormone 
(GH) secreting adenomas are the next most common, reported 
in 5.5–31% and 7.2–25% of cases, respectively [4]. 
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Although PA usually occurs in adenomas, it has also 
been described in non-adenomatous lesions including sellar 
tuberculoma, metastasis to the pituitary, abscess, craniopha-
ryngioma, sellar haemagioblastoma, Rathke’s cleft cyst and 
lymphocytic hypophysistis [3, 4]. 
Pituitary ischaemia can also be seen in other specific cases, 
for example in Sheehan’s syndrome, where a large postpartum 
hypovolemia due to haemorrhage can lead to ischaemic pitui-
tary necrosis within a normal pituitary gland, enlarged during 
pregnancy, with resultant hypopituitarism [11].
Pathophysiology
Several hypotheses exist on the pathogenesis of pituitary 
apoplexy. Both infarction and haemorrhage are observed in 
apoplexy, not always concurrently. Ischaemic necrosis and 
haemorrhagic conversion in any setting reflect an imbalance 
of blood flow and perfusion to the target organ [2]. Previo-
usly proposed mechanisms for pituitary apoplexy include 
reduced blood supply to the tumour produced by events such 
as hypotension, rapid growth outpacing the development 
of adequate blood supply to the tumour, direct pressure by 
the tumour on the portal vessels or the hypophyseal arteries 
causing acute ischaemia, increased intratumoural pressure 
which itself acutely impairs the blood flow to the tumour, 
increased metabolic activity beyond adequate arterial supply 
after stimulation with hypothalamic releasing factors, and ha-
emorrhage resulting from fragility of the tumour vessels [12]. 
There is evidence supporting these proposed mechanisms as 
contributory factors in most cases, but something else seems 
to be needed to explain all cases. 
The observation that pituitary adenomas appear more 
prone to bleeding than other intracranial neoplasms [13] 
has led to further speculation on underlying intratumoural 
vascular fragility and vasculopathy [14]. Furthermore, a sig-
nificant correlation between the intratumoural expression 
of vascular endothelial growth factor (VEGF) [15, 16] and 
tumour necrosis factor (TNFα) [17] and the presence of 
tumour haemorrhage has been found, suggesting a possible 
causal relationship. 
To summarise, pituitary apoplexy is the product of intrin-
sic features of tumours leaving the tumour in a state of tenuous 
balance between high metabolic demand and marginal blood 
supply in relation to the demand, which exist both in large and 
small tumours [12]. This causes vulnerability of the tumour 
to any factor disturbing this balance. 
Various precipitating factors for apoplexy are identified 
in only 20–40% of cases [1, 18]. For many of them a causal 
relationship has not been definitively proven and is evaluated 
differently in different studies. They can mostly be classified 
into one of four categories: 1) acute increase in hypophyseal 
blood flow; 2) reduced blood flow to the pituitary tumour; 3) 
hormonal stimulation of the pituitary gland and tumour; and 
4) coagulation disturbances [2, 3]. The most common possible 
risk factors are: − systemic hypertension [2–4, 18], − major 
surgery, especially cardiac surgery [2–4, 18], − invasive proce-
dures (spinal anaesthesia, lumbar puncture, angiography) [3, 
4], − dynamic tests of pituitary function with releasing factors 
[2–4, 18], − initiation or withdrawal of dopamine agonist the-
rapy [2, 3, 18], − oestrogen or gonadoliberin analogue therapy 
[2, 3, 18, 19], − coagulopathies [2, 3, 18] , − anticoagulant 
or antithrombotic drugs [3, 4, 18], − radiotherapy [2, 4, 18], 
− pregnancy [2, 3, 18, 20], − head trauma [2–4, 18, 21], − large 
size of tumour, especially with cavernous sinus invasion [2, 
19, 22]. However, none of these factors is likely to be solely 
responsible for the occurrence of apoplexy [23].
Clinical presentation
Classically, symptoms evolve for up to two days after the 
onset of apoplexy, although a subacute course is described [2, 
3] and this is largely determined by the extent of haemorrhage, 
oedema and necrosis [18]. Some authors have suggested that 
cases with ischaemic necrosis have a milder clinical course and 
a better outcome then those with haemorrhage or haemorr-
hagic necrosis [24]. The symptoms are believed to result from 
the rapid enlargement of tumour size and pressure on adjacent 
structures, stretching of the hypophyseal capsule, extravasation 
of blood or necrotic material into the subarachnoid space, 
increased intracranial pressure, and exclusion of the secretory 
function of the pituitary gland [2, 9, 18]. 
The earliest and most frequent symptom (90–100%) of 
pituitary apoplexy is a sudden and severe headache, which 
is usually retro-orbital, but can be bifrontal, suboccipital, or 
diffuse in location [9, 18, 23, 25] and may be accompanied 
by nausea and vomiting (40–80%) [2, 4, 9, 23, 25]. Ocular 
palsies or paresis are present in 40–70% of cases [4, 18], due 
to functional impairment of cranial nerves III, IV and VI. 
The third cranial nerve is most frequently affected due to its 
position, closer to the sella and possibly to its compression 
onto the interclinoid ligament [4], but multiple cranial nerve 
palsies (sometimes with nerve V too) and even bilateral lesions 
have been reported [26, 27].  Visual field deficits, specifi-
cally bitemporal haemianopsia, are seen in 47–75% [9, 18], 
decreased visual acuity is reported in 41–56% of cases [4, 9], 
but unilateral or bilateral blindness is rare [1]. Orbital bruit, 
proptosis, lid oedema, isolated Horner’s syndrome and light 
near dissociation are rare orbital manifestations of pituitary 
apoplexy [28]. 
Impaired consciousness is fairly frequent (13–42%) [4]. 
This can range from mild lethargy to stupor and coma [9] 
and is a sign of severity [4]. Potential pathophysiological 
mechanisms include subarachnoid haemorrhage, increased 
intracranial pressure, obstructive hydrocephalus, adrenal in-
sufficiency causing arterial hypotension and hypoglycaemia, 
and hypothalamic compression [9]. 
Acute endocrine dysfunction is also present, complicating 
the clinical picture [1]. Hypopituitarism (usually permanent) 
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is a major manifestation of PA in 71–100% of cases [2, 4]. 
In retrospect, it is often realised that signs and symptoms of 
endocrine abnormalities were present before the apoplectic 
episode [1]. 
The clinical course may be complicated by: subarachnoid 
haemorrhage, intra-ventricular haemorrhage and intracerebral 
haemorrhage. Extravasation of blood from a bleeding pituita-
ry tumour may enter the spaces mentioned, resulting in the 
clinical presentation [29]. Pituitary apoplexy complicated by 
cerebral infarction is rare, too. Two possible mechanisms of 
cerebral infarction have been suggested: vasospasm (which 
may be caused by subarachnoid haemorrhage, the release of 
vasoactive substances from a pituitary adenoma or hypotha-
lamic damage); and mechanical compression (caused by the 
extension of the tumour mass) [30, 31]. As to the affected 
vessels, the cavernous portion or supraclinoid portion of the 
internal carotid artery, anterior cerebral artery and middle 
cerebral artery are most likely to be involved [30].
Diagnosis
Diagnosis is often difficult especially if there is no previous 
history of pituitary pathology (which occurs in 60–80% of 
cases) [4]. However, a high degree of suspicion should exist in 
any patient with a severe, sudden headache [4] with or without 
neuro-ophthalmic signs [18]. 
The differential diagnosis includes a number of conditions 
such as subarachnoid haemorrhage [2–4], bacterial meningitis 
[32], stroke [2, 4, 28], ophthalmoplegic migraine [2, 4], hyper-
tensive encephalopathy [4], cavernous sinus thrombosis [2–4, 
28], carotico-cavernous fistula [28], optic neuritis [2, 28], and 
reversible cerebral vasoconstrictive syndrome (RCVS) [33]. 
It is important to stress that pituitary adenoma co-exist with 
cerebral aneurysms at a rate of 7.4% [3]. 
Brain imaging is required to identify a pituitary lesion 
[3]. Computed tomography (CT) and magnetic resonance 
imaging (MRI) are both useful diagnostic tools [29]. CT is 
usually the initial examination because of its widespread 
availability [3]. However, the absence of haemorrhage on CT 
does not preclude pituitary apoplexy [2]. In a retrospective 
series, a sellar mass was identified in 80–93% of the patients, 
but haemorrhage only in 21–28% of cases [1, 18]. CT is most 
useful in the acute stage (< 72 hours) when haemorrhage 
appears as a focal, multifocal or diffuse hyperdensity in the 
pituitary mass [28]. After this time, blood intensity decreases 
and may be difficult to detect [1]. 
The investigation of choice is MRI [18] because of its 
higher sensitivity. It has been found to confirm the diagnosis 
of pituitary tumour in 100%, and of pituitary apoplexy in 
88%, of cases [1]. MRI also elucidates anatomic detail of the 
underlying tumour, sellar expansion, suprasellar and para-
sellar extension, optic chiasm compression, and cavernous 
sinus involvement [2], but it also has weaknesses. It is the best 
means of identifying blood components in a subacute setting 
from four days up to one month. It cannot replace CT in an 
acute setting, as it is unable to detect fresh blood [1, 4]. Blood 
component density changes with time on MRI; necrosis in the 
tumour is hypointense in T1 but hyperintense in T2 (Tab. 1) 
[1]. Subacute or chronic haemorrhage is frequently identified 
even on non-enhanced MRI studies. Non-haemorrhagic 
Figure 1. Magnetic resonance imaging of pituitary apoplexy in acute phase; Saggital view:  T1-weighted image (left) and T2-weighted image 
(right); Courtesy of Radiology Department, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, A. Jurasz University 
Hospital No 1 in Bydgoszcz (head: Prof. Z. Serafin)
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Table 1. Blood component density changes with time on MRI [1]
T1 T2






Subacute phase: intracellular methaemoglobin (3–5 days)





Chronic phase: haemosiderin (> 3 weeks) hypointense hypointense
MRI — magnetic resonance imaging; T1 — T1-weighted sequences; T2 — T2-weighted sequences 
Table 2. Pituitary Apoplexy Score (PAS) [5, 18]
PAS score
Consciousness level in GCS [points]:
    15
    8–14





    normal or no change from premorbid acuity
    reduced unilateral





    normal 
    unilateral deficit 





    absent
    present unilateral




Minimum = 0 points
Maximum = 10 points
GCS — Glasgow Coma Scale
changes (infarction alone) present as low intensity areas with 
no contrast enhancement [4].
Diagnosis is based on neuroimaging, but equally impor-
tant for the further procedure is evaluation of the secretory 
function of the pituitary. A typical laboratory panel measures 
prolactin (PRL), cortisol, adrenocorticotrophic hormone 
(ACTH), thyroid stimulating hormone (TSH), free thyroxine 
and triiodothyronine (fT4 and fT3), growth hormone (GH), 
follicle stimulating hormone (FSH), luteinising hormone (LH), 
insulin-like growth factor 1 (IGF 1), oestradiol in females, and 
testosterone in males [2]. Clinically, the most crucial deficit is 
that of ACTH, which has been reported in up to 70% of patients 
[3, 18]. Thyrothrophin and gonadothrophin deficiencies are 
observed in 50% and 75% of patients, respectively [3, 18]. 
Every patient should also have a marked concentration 
of electrolytes, renal and liver function, full blood count and 
clotting screen [18]. Hyponatraemia, observed in up to 40% 
of cases, can be secondary to hypocortisolism or (less often) 
inappropriate antidiuretic hormone secretion [3]. 
Patients should also undergo a full ophthalmological 
examination with visual field, visual acuity and ocular paresis 
assessment (within 24 hours of the suspected diagnosis if the 
patient’s condition allows it) [2, 18]. 
Lumbar puncture is of little help in differential diagnosis 
because PA may be accompanied by a high red cell count, 
xantochromia or pleocytosis, and an increased cerebrospinal 
fluid (CSF) protein level, particularly when meningeal irrita-
tion is present. However, CSF culture will rule out bacterial 
meningitis, and lumbar puncture is thus mandatory if this 
diagnostic possibility is raised [1].
Management
Owing to the highly variable course of PA, and to the limi-
ted experience of individual doctors, the optimal management 
of acute episodes remains controversial [1]. In all events, PA 
needs to be managed by a multidisciplinary team including 
a neurologist, neurosurgeon, endocrinologist, ophthalmologist 
and radiologist [1, 28]. 
The first intervention after diagnosis is haemodynamic sta-
bilisation, correction of electrolyte disturbances, and corticoste-
roid administration [2, 3]. Acute secondary adrenal insufficiency 
is the major source of the mortality (0.7–12.5%) [28] associated 
with the condition [18]. Hypocortisolaemia renders the vascula-
ture less responsive to the pressor effects of catecholamines, with 
resultant haemodynamic instability. The mechanisms of fluid 
and electrolyte disturbances are complex. Hypocortisolaemia 
augments vasopressin release from the posterior pituitary and 
has an inhibitory effect on water excretion [18].
Corticosteroids not only decrease the risk of hypoadre-
nalism, but also have significant anti-inflammatory and 
anti-oedematous effects [4]. Indications for empirical steroid 
therapy are haemodynamic instability, altered consciousness 
level, reduced visual acuity and severe visual field deficits 
[18]. Patients who do not fulfil the criteria for urgent empi-
rical steroid therapy should be considered for treatment with 
steroids if their 09:00 serum cortisol is less than 550 nmol/l 
[4, 18]. The administration of hydrocortisone is preferred: 
100–200 mg as an intravenous bolus is appropriate followed 
either by 50–100 mg intravenously or intramuscularly every 
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Figure 2. Magnetic resonance imaging of pituitary apoplexy in subacute phase (3–5 days); Coronal view; T1-weighted image (left) and 
T2-weighted image (right); Courtesy of Radiology Department, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 
A. Jurasz University Hospital No 1 in Bydgoszcz (head: Prof. Z. Serafin)
Figure 3. Magnetic resonance imaging of pituitary apoplexy — 
contrast enhancement; Coronal view; Courtesy of Radiology De-
partment, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus 
University in Toruń, A. Jurasz University Hospital No.1 in Bydgoszcz 
(head: Prof. Z. Serafin)
six hours, or by 2–4 mg per hour by continuous intravenous 
infusion [1, 18]. The role of dexamethasone in high doses (up 
to 16 mg/day) instead of stress dose hydrocortisone has not 
been formally evaluated in acute PA, but its use has been repor-
ted in a number of cases, especially where an anti-oedematous 
effect is sought [4, 5]. 
Following stabilisation, the most crucial decision is 
whether the clinical situation requires surgical intervention 
or medical treatment [9]. 
Traditionally, most patients with apoplexy were treated 
surgically after this initial stabilisation. However, recent studies 
have repeatedly reported good outcomes in selected patients 
treated conservatively with medical therapy only [23]. Because 
of the rarity of this disease and the small groups to compare, 
recommendations require an individual evaluation, but also 
further multicentre trials [4]. 
The Pituitary Apoplexy Guidelines Development Group 
formed in the United Kingdom established the following 
guidelines: 1. surgery is indicated if there are disturbances of 
consciousness, visual field defects and impaired visual acuity; 
2. conservative therapy may be used in patients without these 
disorders (or when symptoms decrease), and if there is only 
ophthalmoparesis or ophthalmoplegia; and 3. during conser-
vative treatment constant supervision of the patient is needed 
and in the event of deterioration the indications for surgery 
should be reconsidered [18]. 
Ocular paresis because of the involvement of III, IV or VI 
cranial nerves in the absence of visual field defects or reduced 
visual acuity is not in itself an indication for immediate sur-
gery [18] because the three ocular motor cranial nerves are 
peripheral nerves and can undergo regeneration, whereas the 
optic nerve, as part of the white matter, cannot recover after 
axonal disruption [21]. 
To help in the objective assessment of clinical severity, 
to quantify neuro-ophthalmological defects and to monitor 
conservatively managed patients, a scoring system named the 
Pituitary Apoplexy Score (PAS) has been designed in the UK 
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(Tab. 2) [5, 18]. The result can be from 0 to 10 points. Clinical 
severity based on PAS ≥ 4 (applied retrospectively) appears 
to influence the management of patients towards emergency 
surgical intervention [4, 5]. This scoring system could also help 
audit the outcome in surgically and conservatively managed 
patients [18]. 
Some authors from the USA have proposed another 
grading system which defines pituitary apoplexy radiograp-
hically as a sellar mass lesion with suspected haemorrhage or 
necrosis and categorises patients into five grades of increasing 
clinical severity based on the most common presenting symp-
toms. Grade 1 patients are asymptomatic, grade 2 patients 
have symptoms attributable only to endocrinopathy, grade 
3 patients have a headache, grade 4 patients have ocular paresis, 
and grade 5 patients have visual deficits or a low GCS score 
such that vision cannot be assessed [34]. Patients with a higher 
grade (4–5) require timely surgical management, and patients 
with a lower grade (1–3) may be treated with elective surgery 
or even conservative management [34]. 
If surgery is decided upon, it should be performed pre-
ferably within seven days of the onset of symptoms [2, 18]. 
Transsphenoidal surgery is preferred, due to its low morbidity 
and mortality rates [4]. Most neurosurgeons now prefer an 
endoscope to an operative microscope [1]. If severe comor-
bidities contraindicate early surgery, a conservative approach 
is initially taken and a delayed intervention (if possible) may 
offer some prospect of improvement [4].
Outcomes and aftermaths
In most series, a comparison between the two approa-
ches is not possible due to the selection bias as patients most 
severely affected were directed towards surgery. Bearing this 
in mind, it seems that the visual and endocrine outcomes are 
similar in operated and conservatively managed cases [1, 4, 
5, 23]. Oculomotor palsies improve in 63–100% of patients 
with surgery [4] and in 64–100% of patients managed con-
servatively [1]. Visual field deficits improve after surgery in 
57–95% of cases [4] and in 50–100% of cases conservatively 
managed [1, 4]. Visual acuity normalised in 86–93% of 
patients after surgery [4] and in 80–100% of conservatively 
managed cases [4]. 
A PA event can lead to irreversible loss of pituitary cells, 
thus leaving the majority of patients with (at least partial) pi-
tuitary insufficiency [21]. Pituitary function recovers partially 
or completely in up to 50% of patients [1, 18]. Pituitary insu-
fficiency usually develops following haemorrhagic apoplexy, 
whereas pituitary function is more commonly preserved after 
infarctive apoplexy [35]. Nearly 80% of patients will need some 
form of hormone replacement after apoplexy [18]. Growth 
hormone deficiency is the most commonly observed deficit. 
It is present in almost all patients but is rarely replaced [18]. 
Long-term hormone replacement therapy following pituita-
ry apoplexy consists of corticosteroids in 40–80%, thyroid 
hormone in 45–60%, desmopressin in 2–11%, and gonado-
throphins in 55–80% of patients [2, 4, 18]. 
One argument in favour of the surgical approach is that 
surgery can remove the pituitary tumour. However, many 
patients have no visible tumour remnant after an apoplectic 
episode managed conservatively [1]. There are a few studies 
comparing the incidence of tumour recurrence after apoplexy, 
and these show that tumour regrowth is possible both in the 
group treated surgically and in the group treated conservati-
vely, varying according to different studies from 4% to 22% 
of cases [1, 36–40]. Thus, the respective merits of the two 
approaches in terms of tumour control are currently difficult 
to judge [1].
Long-term monitoring
All patients who have been treated for apoplexy (both 
surgically and conservatively) need long-term endocrine and 
imaging follow-up [3, 18]. Pituitary imaging (MRI) is recom-
mended at 3–6 months after apoplexy, then annually for the 
first five years and biennially thereafter [4, 18]. All patients 
should have an endocrine review at 4–8 weeks following the 
event and then once a year [3, 18]. Assessment of pituitary 
function should include fT4, TSH, LH, FSH, testosterone in 
men, oestradiol in women, PRL, IGF-1 and dynamic tests of 
cortisol and growth hormone secretion if clinically appropriate 
[18]. Formal assessment of visual acuity, eye movements and 
visual field is also needed at 4–8 weeks following the event [18].
Conclusions
Pituitary apoplexy is a rare, potentially life-threatening 
clinical syndrome, caused by haemorrhage or ischaemic 
infarction of the pituitary gland, generally within a pituitary 
adenoma. PA can mimic a wide spectrum of clinical condi-
tions, but the constellation of signs must alert the clinician to 
the possibility of this disease. CT or MRI imaging confirms the 
diagnosis. Haemodynamic stabilisation, reversal of electrolyte 
imbalance, and correction of corticotrophic deficiency must 
therefore always be initiated immediately. Further treatment 
includes both conservative management and consideration 
for neurosurgical intervention. The procedure should be 
established multidisciplinarily and involve the cooperation 
of a neurologist, neurosurgeon, endocrinologist and ophthal-
mologist. Appropriate intervention is associated with good 
neuro-ophthalmic recovery. The endocrinological prognosis 
is less favourable, with many patients requiring replacement 
therapy. In view of the risk of tumour regrowth, long-term 
follow-up is necessary. It would be advisable to conduct multi-
-centre, randomised clinical trials to determine the optimal 
management of pituitary apoplexy.
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